In the last trading session, 1.01 million shares of the Beam Therapeutics Inc (NASDAQ:BEAM) were traded, and its beta was 1.91. Most recently the company’s share price was $26.57, and it changed around -$0.84 or -3.06% from the last close, which brings the market valuation of the company to $2.20B. BEAM currently trades at a discount to its 52-week high of $49.50, offering almost -86.3% off that amount. The share price’s 52-week low was $20.84, which indicates that the current value has risen by an impressive 21.57% since then. We note from Beam Therapeutics Inc’s average daily trading volume that its 10-day average is 0.95 million shares, with the 3-month average coming to 1.15 million.
Beam Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.76. If we narrow it down even further, the data shows that 0 out of 16 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 6 recommended BEAM as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. Beam Therapeutics Inc is expected to report earnings per share of -1.22 for the current quarter.
Beam Therapeutics Inc (NASDAQ:BEAM) trade information
Instantly BEAM has showed a red trend with a performance of -3.06% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 28.95 on recent trading dayincreased the stock’s daily price by 8.22%. The company’s shares are currently up 7.14% year-to-date, but still up 3.83% over the last five days. On the other hand, Beam Therapeutics Inc (NASDAQ:BEAM) is -0.86% down in the 30-day period. We can see from the shorts that 10.79 million shares have been sold at a short interest cover period of 8.25 day(s).
The consensus price target as assigned by Wall Street analysts is $48, which translates to bulls needing to increase their stock price by 44.65% from its current value. Analyst projections state that BEAM is forecast to be at a low of $37 and a high of $69.
Beam Therapeutics Inc (BEAM) estimates and forecasts
The year-over-year growth rate is expected to be -86.39%, down from the previous year.
Consensus estimates provided by 13 financial analysts predict the company will bring in an average of 16.47M in revenue for the current quarter. 5 analysts expect Beam Therapeutics Inc to make 15.15M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 316.19M and 7.41M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -94.79%. Forecasts for the next quarter put sales growth at 104.50%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 5.58%.
BEAM Dividends
Beam Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Beam Therapeutics Inc (NASDAQ:BEAM)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.51% of Beam Therapeutics Inc shares, and 94.57% of them are in the hands of institutional investors. The stock currently has a share float of 96.02%. Beam Therapeutics Inc stock is held by 333.0 institutions, with FARALLON CAPITAL MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 9.6857% of the shares, which is about 7.91 million shares worth $185.4 million.
VANGUARD GROUP INC, with 9.6701% or 7.9 million shares worth $185.11 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 4.78 shares worth $127.04 million, making up 5.77% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 2.34 shares worth around $62.09 million, which represents about 2.82% of the total shares outstanding.
